Ignite Creation Date:
2024-05-05 @ 5:20 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00437918
Status:
COMPLETED
Last Update Posted:
2008-03-24
First Post:
2007-02-20
Brief Title:
The Effects of Nateglinide and Acarbose on the Post-Prandial Glucose Control in Type 2 Diabetic Patients
Sponsor:
Inje University
Organization:
Inje University
Study Overview
Official Title:
Phase IV Study on Predictive Markers for the Effectiveness of Nateglinide or Acarbose for Controlling Post-Prandial Glucose in Type 2 Diabetics Already on Optimized Insulin Glargine Therapy
Status:
COMPLETED
Status Verified Date:
2008-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In type 2 diabetic patients tight blood glucose control often requires both fasting and post-prandial glucose control separately In the diabetic patients already on the insulin glargine treatment for the control of fasting blood glucose additional measures for the control of post-prandial glucose level are often required Nateglinide and acarbose are frequently used for this purpose We hypothesized that the short acting sulfonylurea nateglinide may be more efficacious in diabetic patients with appreciable endogenous insulin secretion while acarbose may be more efficacious in patients with lower endogenous insulin secretion And we also want to clarify the clinical and biochemical parameters that can predict the responsiveness to each agent in this multi-center randomized open cross-over clinical study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None